SCHEMBL115146

SCHEMBL115146

NNc1ccccc1[C]=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA6 P23280 1/20 0.43
CA5A P35218 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA5B Q9Y2D0 1/20 0.43
TDP1 Q9NUW8 3/20 0.39
ALDH1A1 P00352 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
POLB P06746 1/20 0.39
LMNA P02545 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
IDO1 P14902 1/20 0.35
CYP2C19 P33261 1/20 0.35
PTGS2 P35354 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3878150 0.80 KDM4E (0.33) TDP1ALDH1A1L3MBTL1LMNACYP1A2
SCHEMBL244118 0.76 KDM4E (0.43) TDP1ALDH1A1L3MBTL1POLBLMNA
SCHEMBL1781557 0.76 KDM4E (0.52) CA12CA1CA2CA9ALDH1A1
Hydrochloric Acid SCHEMBL31549660 0.74 KDM4E (0.50) CA12CA1CA2CA9TDP1
Bromide SCHEMBL20984459 0.74 KDM4E (0.50) CA12CA1CA2CA9ALDH1A1
Hydrochloric Acid SCHEMBL1821629 0.74 KDM4E (0.50) CA12CA1CA2CA9TDP1
Hydrochloric Acid SCHEMBL28768961 0.74 TDP1 (0.47) CA12CA1CA2CA6CA5A
SCHEMBL6300024 0.73 TSHR (0.44) ALDH1A1L3MBTL1LMNAGAAKDM4E
SCHEMBL96064 0.73 MAPT (0.50) TDP1ALDH1A1L3MBTL1LMNACYP1A2
SCHEMBL5358661 0.73 GAA (0.39) CA12CA1CA2CA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4100007-A1 ELONGATION FACTOR 1-ALPHA INHIBITORS AND USES THEREOF The Regents of the University of California (US) 2022-12-14 EP claimed
WO-2021158899-A1 ELONGATION FACTOR 1-ALPHA INHIBITORS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-08-12 WO claimed
EP-4370528-A1 AQUEOUS SOLID PHASE PEPTIDE SYNTHESIS Polypeptide Laboratories Holding (PPL) AB (SE) 2024-05-22 EP disclosed
CN-117897392-A Aqueous solid phase peptide synthesis 多肽实验室(PPL)控股公司 2024-04-16 CN disclosed
US-20230135758-A1 ELONGATION FACTOR 1-ALPHA INHIBITORS AND USES THEREOF UNIV CALIFORNIA (US) 2023-05-04 US disclosed
US-20230107647-A1 SINGLE MOLECULE PEPTIDE SEQUENCING BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-04-06 US disclosed
WO-2023287345-A1 AQUEOUS SOLID PHASE PEPTIDE SYNTHESIS POLYPEPTIDE LABORATORIES HOLDING (PPL) AB (SE) 2023-01-19 WO disclosed
EP-4100007-A1 ELONGATION FACTOR 1-ALPHA INHIBITORS AND USES THEREOF The Regents of the University of California (US) 2022-12-14 EP disclosed
US-20220185841-A1 METHOD FOR PRODUCING PEPTIDE COMPOUND, REAGENT FOR FORMING PROTECTIVE GROUP, AND HYDRAZINE DERIVATIVE FUJIFILM CORPORATION (JP) 2022-06-16 US disclosed
EP-4011902-A1 METHOD FOR PRODUCING PEPTIDE COMPOUND, REAGENT FOR FORMING PROTECTING GROUP, AND HYDRAZINE DERIVATIVE FUJIFILM Corporation (JP) 2022-06-15 EP disclosed
US-11162952-B2 Single molecule peptide sequencing BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-11-02 US disclosed
EP-1910826-A2 MICROSTRUCTURE AND MICRODOMAIN MICROARRAYS, METHODS OF MAKING AND USING THEREOF Arizona Board of Regents, acting for and on behalf of Arizona State University (US) 2008-04-16 EP disclosed
US-20080008649-A1 Gastrin Releasing Peptide Compounds BRACCO IMAGING S.P.A. (IT) 2008-01-10 US disclosed
WO-2006138479-A2 MICROSTRUCTURE AND MICRODOMAIN MICROARRAYS, METHODS OF MAKING AND USING THEREOF ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2006-12-28 WO disclosed
US-20060018830-A1 Gastrin releasing peptide compounds BRACCO IMAGING S.P.A. (IT) 2006-01-26 US disclosed
WO-2005118634-A2 HELICAL PEPTIDOMIMETICS WITH ENHANCED ACTIVITY AGAINST BETA-AMYLOID PRODUCTION THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2005-12-15 WO disclosed
US-20050272659-A1 Helical peptidomimetics with enhanced activity THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2005-12-08 US disclosed
WO-2005108992-A1 MICROARRAY OF THREE-DIMENSIONAL HETEROPOLYMER MICROSTRUCTURES AND METHOD THEREFOR ARIZONA BOARD OF REGENTS, ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2005-11-17 WO disclosed
WO-2003105751-A2 NOVEL CURCUMIN DERIVATIVES KWON HO-JEONG (KR) 2003-12-24 WO disclosed
EP-0184363-A2 Enzyme conjugates and their therapeutical use BEECHAM GROUP PLC (GB) 1986-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230107647-A1 SINGLE MOLECULE PEPTIDE SEQUENCING QPCTL, ANPEP, VIP CA12 2991/4885CA1 2934/4885CA2 3496/4885
US-20220185841-A1 METHOD FOR PRODUCING PEPTIDE COMPOUND, REAGENT FOR FORMING PROTECTIVE GROUP, AND HYDRAZINE DERIVATIVE VIP, HRH1, NGLY1 CA12 873/4885CA1 267/4885CA2 2504/4885
US-20080008649-A1 Gastrin Releasing Peptide Compounds GRPR, SSTR5, GIPR CA12 207/4885CA1 301/4885CA2 377/4885
US-20060018830-A1 Gastrin releasing peptide compounds GRPR, GIPR, CCKBR CA12 267/4885CA1 294/4885CA2 742/4885
US-11162952-B2 Single molecule peptide sequencing MICA, ANPEP, VIP CA12 3473/4885CA1 4419/4885CA2 4388/4885
US-20230135758-A1 ELONGATION FACTOR 1-ALPHA INHIBITORS AND USES THEREOF EEF1A1, EEF1B2, EEF1G CA12 4879/4885CA1 4845/4885CA2 4843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.